Key Highlights

  • Curis (NASDAQ:CRIS) climbed 68.20% intraday to USD 1.2008 on Volume of 116.74 million shares, though no company announcement dated November 2 to November 4, 2026 was identified.
  • Lyell Immunopharma (NASDAQ:LYEL) traded at USD 14.28, up 32.59%, after a USD 80 million gross private Placement priced at USD 10.77, which arrived together with updated ronde-cel data.
  • Nurix Therapeutics (NASDAQ:NRIX) sank 41.91% to USD 15.00 after Sanofi halted the Phase 1 trial of oral STAT6 degrader SAR448272 and ended the program, according to a November 3, 2026 release.
  • BioVie (NASDAQ:BIVI) traded at USD 1.40, down 19.08%, following USD 4.74 million of gross proceeds from a registered direct offering at USD 1.60 with warrants at USD 1.70.

Curis (NASDAQ:CRIS): Up 68.20% With No Identified Catalyst

Curis (NASDAQ:CRIS) gained 68.20%, or USD 0.4869, to USD 1.2008 in intraday trade on November 4, 2026, from an implied previous close of about USD 0.7139 (calculated). Volume reached 116.74 million shares, roughly 19 times the screener's relative-volume baseline, and market Capitalization was close to USD 8 million. No company release or filing dated November 2 to November 4, 2026 was identified, so the move appears trading-driven. The background includes an October 16, 2026 private placement of about USD 8.5 million at an effective USD 0.51 per share, with new warrants at USD 0.60 and earlier warrants repriced to USD 0.60. Lower exercise prices make dilution more probable if the stock remains above USD 0.60. The company states its cash will not cover 12 months, and initial CLL data from 5 to 10 patients are guided for December 2026. With such a small market value, a few trades can move the price and quoted moves may reverse. Heavy volume in a low-priced biotech often reflects short-term traders rather than a shift in the outlook. A July 22, 2026 company release reported a 33% overall response rate (10 of 30 evaluable patients) for emavusertib in BTK inhibitor experienced primary central nervous system lymphoma. The next offering or Warrant exercise could press the price again, and the move gives no sign it will persist.

Lyell Immunopharma (NASDAQ:LYEL): Up 32.59% on a USD 80 Million Raise

Lyell Immunopharma (NASDAQ:LYEL) rose USD 3.51, or 32.59%, to USD 14.28 on November 4, 2026. That implies a November 3 close of about USD 10.77 (calculated), matching the placement price in the company release. At 9:02 a.m. ET the firm announced a private placement of 7,428,040 shares for roughly USD 80 million gross, with Goldman Sachs and Leerink Partners acting as placement agents and ARCH Venture Partners, Adage Capital Management, Caligan Partners and RTW Investments among the buyers. A release the same day reported a 91% response rate and a 77% complete response rate across 44 evaluable third-line patients for ronde-cel, figures reported by the company and drawn from a single-arm cohort. Cash is expected to last into 2028. The new shares are unregistered and carry resale registration rights on Form S-3, so later registration could add supply. Volume was only 166.58 thousand shares. Pricing at the prior close meant there was no discount. Management said proceeds will fund ronde-cel pivotal trials, LYL273 for colorectal cancer and working capital, with pivotal data expected in mid-2027 and a BLA submission in the second half of 2027. The company is pre-revenue, no approval is assured, and quoted gains on modest volume can reverse.

Nurix Therapeutics (NASDAQ:NRIX): Down 41.91% After Sanofi Ends a Program

Nurix Therapeutics (NASDAQ:NRIX) fell 41.91%, or USD 10.82, to USD 15.00 on November 4, 2026, from an implied previous close of about USD 25.82 (calculated). The catalyst was a company release dated November 3, 2026, published after the market closed, saying partner Sanofi had chosen to halt the Phase 1 trial of SAR448272 and end the program, with no reason given. Nurix no longer anticipates milestones or royalties from it. Cash and marketable securities totaled USD 1.1 billion at August 31, 2026, and cash guidance still extends into the second half of 2029, with no change. Jefferies reportedly reduced its price target from USD 45 to USD 36 while keeping a Buy rating, per published coverage. The lead BTK degrader bexobrutideg is in Phase 3 with Roche, which leaves the company dependent on a single partner. Sanofi exercised a license extension option in 2025 covering two transcription Factor programs, and Nurix retains an option to co-develop and co-promote in the United States after clinical proof of concept. Early-stage programs can be dropped by partners with little warning, and partnered Revenue can vanish when that happens. The release listed no upcoming catalysts.

BioVie (NASDAQ:BIVI): Down 19.08% After a USD 4.74 Million Offering

BioVie (NASDAQ:BIVI) was quoted at USD 1.40, down 19.08%, or USD 0.33, on November 4, 2026, from an implied prior close of USD 1.73 (calculated). A company release dated that day priced a registered direct offering of 2,962,500 shares at USD 1.60, with matching unregistered warrants at USD 1.70 exercisable six months after issuance, for approximately USD 4.74 million gross. The Offer Price sits below the calculated prior close, which explains much of the decline. Against a market capitalization of about USD 11.94 million, the raise equals roughly 40% of that value (simple arithmetic on two published figures). Closing is expected on or about November 5, 2026, and proceeds will go to working capital. Volume was 419.09K shares, so spreads can be wide and quoted moves may reverse. A registered direct offering issues new shares, usually priced near or below the last trade, so each existing share represents a smaller portion of the company. The warrants could add 2,962,500 more shares if exercised, although the USD 1.70 strike is above the current quote. Nothing here suggests the decline will continue.

Where Things Stand

Biotech moves are being driven by financing and partner news rather than approvals. Curis (NASDAQ:CRIS) is up 68.20% with no identified announcement. Lyell Immunopharma (NASDAQ:LYEL) gained 32.59% after a USD 80 million placement and company-reported ronde-cel data. Nurix Therapeutics (NASDAQ:NRIX) dropped 41.91% after Sanofi ended SAR448272. BioVie (NASDAQ:BIVI) fell 19.08% following its offering. The next markers are the ASH presentations in December 2026, Curis CLL data in December 2026, and the BioVie closing on or about November 5, 2026.